Back to Search Start Over

Promoter polymorphisms in the chitinase 3-like 1 gene influence the serum concentration of YKL-40 in Danish patients with rheumatoid arthritis and in healthy subjects

Authors :
Julia S. Johansen
Merete Lund Hetland
Mette Nyegaard
Kaspar René Nielsen
Sophine B. Krintel
Hans Erik Johnsen
Søren Lundbye-Christensen
Rudi Steffensen
John Bæch
Martin Boegsted
Source :
Nielsen, K R, Steffensen, R, Boegsted, M, Baech, J, Lundbye-Christensen, S, Hetland, M L, Krintel, S B, Johnsen, H E, Nyegaard, M & Johansen, J S 2011, ' Promoter polymorphisms in the chitinase 3-like 1 gene influence the serum concentration of YKL-40 in Danish patients with rheumatoid arthritis and in healthy subjects ', Arthritis research & therapy, vol. 13, no. 3, pp. R109 . https://doi.org/10.1186/ar3391, Arthritis Research & Therapy
Publication Year :
2011
Publisher :
Springer Science and Business Media LLC, 2011.

Abstract

Introduction The present study investigates the association between single nucleotide polymorphisms (SNPs) in the chitinase 3-like 1 (CHI3L1) gene and serum concentrations of YKL-40 in Danish patients with rheumatoid arthritis (RA) and healthy controls as well as the association with RA in the Danish population. The CHI3L1 gene is located on chromosome 1q32.1 and encodes the YKL-40 glycoprotein. YKL-40 concentrations are elevated in the serum of patients with RA compared to healthy subjects, and YKL-40 has been suggested to be an auto-antigen and may play a role in development of RA and in inflammation. Methods Eight SNPs in the CHI3L1 gene and promotor were genotyped in 308 patients with RA and 605 controls (healthy blood donors) using TaqMan allele discrimination assays. Serum concentrations of YKL-40 were determined by an enzyme-linked immunosorbent assay (ELISA). Results We found significant association between the serum concentrations of YKL-40 and polymorphism in the CHI3L1 gene among both patients with RA and controls. The g.-131(C > G) polymorphism (rs4950928) was most strongly associated with age adjusted serum concentrations of YKL-40 in patients with RA (P < 2.4e-8) and controls (P < 2.2e-16). No significant allelic- or genotypic association with RA was found in this Danish cohort. Conclusions We suggest that the g.-131(C > G) promoter polymorphism has a substantial impact on serum concentrations of YKL-40 in patients with RA and healthy subjects. However, the polymorphism does not seem to confer risk to RA itself. The effect of CHI3L1 polymorphism on clinical outcome or the response to treatment in patients with RA remains to be investigated.

Details

ISSN :
14786354
Volume :
13
Database :
OpenAIRE
Journal :
Arthritis Research & Therapy
Accession number :
edsair.doi.dedup.....635b8e631cffe7e0ebb3c91c52739840
Full Text :
https://doi.org/10.1186/ar3391